Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment

INTRODUCTION: Droxidopa is approved to treat neurogenic orthostatic hypotension (nOH) symptoms in patients with autonomic failure based on short-term clinical trial data. Additional data on the long-term efficacy of droxidopa are needed. We have evaluated the 12-week efficacy and tolerability of dro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Favit, Antonella, Hewitt, L. Arthur, Lindsten, Annika, Gorny, Stephen, Kymes, Steven, Isaacson, Stuart H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857381/
https://www.ncbi.nlm.nih.gov/pubmed/35107750
http://dx.doi.org/10.1007/s40120-021-00317-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857381/
https://www.ncbi.nlm.nih.gov/pubmed/35107750
http://dx.doi.org/10.1007/s40120-021-00317-5

Ejemplares similares